Histoplasmosis¶
Chapter 218 | Part 5: Infectious Diseases
KEY CLINICAL POINTS¶
- Histoplasmosis is caused by Histoplasma capsulatum, a dimorphic fungus endemic in North America, Central/South America, Africa, and Asia.
- Clinical manifestations range from asymptomatic to life-threatening disseminated disease, with severity dependent on immune status and exposure intensity.
- Diagnosis relies on Histoplasma antigen detection (BAL, CSF, urine), serology, and fungal cultures, with treatment guided by disease severity and immune status.
- Itraconazole is first-line for mild-to-moderate cases; amphotericin B is used for severe or disseminated disease, with prolonged antifungal therapy required for chronic/cavitary forms.
- Immunocompromised patients (e.g., HIV/AIDS, transplant recipients) are at highest risk for progressive disseminated histoplasmosis (PDH).
1. DEFINITION & OVERVIEW¶
Histoplasmosis is a fungal infection caused by Histoplasma capsulatum, a dimorphic fungus. It is the most common endemic mycosis in North America. The disease presents as asymptomatic infection, acute pulmonary illness, or progressive disseminated histoplasmosis (PDH), with severity influenced by immune status and exposure intensity. The yeast form of the fungus replicates in the lungs, while mycelia form in soil.
1.1 Pathogenesis¶
Inhalation of microconidia leads to phagocytosis by alveolar macrophages, where they transform into yeast. Immune responses, particularly T-cell-mediated immunity, control infection. In immunocompromised hosts, dissemination to systemic organs occurs.
1.2 Variants¶
Histoplasma capsulatum has two main variants: var. capsulatum (North America, Central/South America) and var. duboisii (Africa). Var. duboisii causes distinct clinical presentations with frequent skin and bone involvement.
2. EPIDEMIOLOGY¶
Histoplasmosis is endemic in the Ohio and Mississippi River valleys, parts of Mexico, Central/South America, Africa, and Asia. Risk factors include exposure to bird/bat droppings, occupations (e.g., spelunking, construction), and immunosuppression (e.g., HIV/AIDS, organ transplant recipients, autoimmune disorders).
2.1 Demographics¶
Most prevalent in adults from endemic areas; up to 75% of adults in endemic regions have asymptomatic prior infection. Children and immunocompromised individuals are at higher risk for severe disease.
2.2 Global Trends¶
Increasing reports outside traditional endemic areas due to climate change, travel, and expanding at-risk populations. African histoplasmosis caused by var. duboisii is distinct and often severe.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
Histoplasma capsulatum is a thermal dimorphic fungus. In soil, it exists as mycelia; in host tissues, it becomes yeast. Pathogenesis involves phagocytosis, transformation to yeast, immune evasion, and dissemination in immunocompromised hosts. Iron and calcium availability in phagocytes are critical for yeast survival.
3.1 Immune Response¶
T-cell-mediated immunity (IFN- γ , TNF- α ) is essential for controlling infection. In immunocompetent hosts, granulomas form and contain the fungus. In immunocompromised hosts, dissemination occurs.
3.2 Complications¶
Fibrosing mediastinitis, broncholithiasis, and disseminated disease. Chronic pulmonary histoplasmosis mimics tuberculosis with cavitation and fibrosis.
4. CLINICAL FEATURES¶
Clinical manifestations range from asymptomatic infection to life-threatening PDH. Acute pulmonary histoplasmosis presents with flu-like symptoms (fever, cough, chest pain). Chronic/cavitary disease involves cough, weight loss, and lung nodules. Disseminated disease affects multiple organs (liver, spleen, adrenal glands).
4.1 Acute Pulmonary¶
Fever, chills, myalgia, dry cough, and chest pain. Chest X-ray shows hilar/mediastinal lymphadenopathy and pulmonary infiltrates.
4.2 Chronic/Cavitary¶
Productive cough, dyspnea, low-grade fever, night sweats, and weight loss. Chest X-ray shows upper lobe infiltrates and cavitation.
4.3 Disseminated¶
Involves lungs, bone marrow, liver, adrenal glands, and mucocutaneous membranes. May present with meningitis, adrenal insufficiency, or hemoptysis.
5. DIFFERENTIAL DIAGNOSIS¶
Differential diagnoses include tuberculosis, coccidioidomycosis, blastomycosis, cryptococcosis, and other fungal infections. Consider TB in immunocompetent patients and other mycoses in immunocompromised hosts.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnosis relies on Histoplasma antigen detection (BAL, CSF, urine), serology (ID, CF, EIA), and fungal cultures. Antigen testing is rapid and highly sensitive for PDH. Imaging (chest CT) may show lung nodules or mediastinal lymphadenopathy.
Table 218-1: Recommendations for Diagnosis and Treatment of Histoplasmosis¶
| TYPE OF HISTOPLASMOSIS | DIAGNOSTIC TESTS | TREATMENT RECOMMENDATIONS | COMMENTS |
|---|---|---|---|
| Acute pulmonary, mild to moderate with no improvement by the time of diagnosis | Histoplasma antigen (BAL fluid, serum, urine) Cytopathology and fungal culture of BAL fluid Histoplasma serology (ID and CF), (EIA): IgG and IgM | Itraconazole (200 mg bid) for 6–12 weeks. Monitor renal and hepatic function. | Patients with mild cases usually recover without therapy, but itraconazole should be considered if the patient’s condition is not improving by the time of diagnosis. |
| Acute pulmonary, severe illness, respiratory failure (ARDS) | Histoplasma antigen (BAL fluid, serum, urine) Cytopathology and fungal culture of BAL fluid Histoplasma serology (ID and CF), (EIA): IgG and IgM | Lipid AmB (3–5 mg/kg per day) ± glucocorticoids for 1–2 weeks; then itraconazole (200 mg bid) for 6–12 weeks. Monitor renal and hepatic function. | |
| Chronic/cavitary pulmonary | Histoplasma serology (ID and CF), (EIA): IgG and IgM Fungal culture of sputum or BAL fluid | Itraconazole (200 mg bid) Adjust dose to achieve blood levels of 2–5 mg/mL for at least 12 months. Monitor hepatic function. | Continue treatment until radiographic findings show no further improvement. Monitor for relapse after treatment is stopped. |
| Progressive disseminated | Histoplasma antigen (BAL fluid, serum, urine) Histoplasma serology (ID and CF), (EIA): IgG and IgM Fungal culture of blood or bone marrow aspirate Cytopathology on biopsy of affected organ | Lipid AmB (3–5 mg/kg per day) for 1–2 weeks; then itraconazole (200 mg bid); adjust dose to achieve blood levels of 2–5 mg/mL for at least 12 months. Monitor renal and hepatic function. | |
| Central nervous system | Histoplasma antigen CSF Histoplasma serology (ID and CF), (EIA): IgG and IgM Fungal culture of CSF | Liposomal AmB (5 mg/kg per day) for 4–6 weeks; then itraconazole (200 mg bid) Adjust dose to achieve blood levels of 2–5 mg/mL for at least 12 months. Monitor renal and hepatic function. | A longer course of lipid AmB is recommended due to high relapse risk. Itraconazole should continue until CSF or MRI abnormalities clear. |
6.1 Diagnostic Tests¶
Histoplasma antigen detection (most sensitive), serology (IgG/IgM), fungal cultures, and imaging. Antigen testing is preferred for rapid diagnosis in resource-limited settings.
6.2 Imaging¶
Chest CT may reveal asymptomatic lung nodules in endemic areas. Diffuse infiltrates or cavitation suggest chronic or acute disease.
7. MANAGEMENT & TREATMENT¶
Treatment depends on disease severity and immune status. Itraconazole is first-line for mild-to-moderate cases; amphotericin B is used for severe or disseminated disease. Posaconazole and isavuconazole are alternatives. Antiretroviral therapy is critical for HIV-positive patients.
7.1 Antifungal Therapy¶
Itraconazole (200 mg bid) for 6–12 weeks for acute pulmonary; prolonged therapy ( ≥ 1 year) for chronic/cavitary. Amphotericin B (lipid formulation) for severe cases. Posaconazole/isavuconazole as alternatives for patients unable to tolerate itraconazole.
7.2 Monitoring¶
Monitor drug levels (itraconazole: 2–5 µ g/mL), renal/hepatic function, and antigen levels. Adjust dosages for drug interactions (e.g., P450 inhibitors).
7.3 Special Populations¶
Avoid posaconazole in pregnancy. Reduce immunosuppression where possible; antiretroviral therapy improves outcomes in HIV/AIDS patients.
8. PROGNOSIS & COMPLICATIONS¶
PDH has poor prognosis without treatment. Complications include disseminated disease, fibrosing mediastinitis, meningitis, and adrenal insufficiency. Chronic pulmonary disease may mimic tuberculosis with fibrosis and cavitation.
8.1 Mortality¶
PDH is fatal in up to one-third of cases without treatment. Mortality is higher in immunocompromised patients.
8.2 Long-term Effects¶
Chronic pulmonary disease may lead to progressive fibrosis. Fibrosing mediastinitis can cause airway obstruction and superior vena cava syndrome.
9. SPECIAL CONSIDERATIONS¶
Pregnancy: Avoid posaconazole. Pediatrics: Monitor for severe disease in immunocompromised children. Elderly: Consider comorbidities and drug interactions. HIV/AIDS patients require antiretroviral therapy and prolonged antifungal treatment.
9.1 Drug Interactions¶
Itraconazole interacts with P450 enzymes; avoid concurrent use with other P450 substrates. Posaconazole has significant P450 interactions.
9.2 Antiretroviral Therapy¶
Antiretroviral therapy improves outcomes in HIV-positive patients with PDH. Delaying treatment may increase risk of immune reconstitution inflammatory syndrome (IRIS).
10. KEY POINTS & CLINICAL PEARLS¶
Histoplasmosis is endemic in North America and other regions; diagnosis relies on antigen testing and imaging. Itraconazole is first-line for mild-to-moderate cases; amphotericin B for severe disease. PDH requires prolonged antifungal therapy. Monitor drug levels and renal/hepatic function. Antiretroviral therapy is critical for HIV-positive patients.